

1 **Methods**

2

3 **Preparation of expression vectors**

4 Custom HELQ ORF was purchased from GeneArt and used as template during PCR to prepare plasmid
5 (pFastbac1) compatible for bacmid preparation for the expression in insect cells. To prepare MBP-HELQ-
6 FLAG construct, HELQ was amplified by PCR using primers HELQ_F and HELQ_FLAG_R. The amplified
7 insert was digested with BamHI and XmaI and inserted into pFastbac1 vector containing MBP (maltose
8 binding protein tag; previously inserted using EcoRV and HindIII restrictions sites). The resulting construct
9 was pFB-MBP-HELQ-FLAG. To prepare helicase dead HELQ K365M, pFB-MBP-HELQ-FLAG was
10 mutagenized with primers HELQ_K365M_F and HELQ_K365M_R using Q5 site-directed mutagenesis
11 kit, according to manufacturer's instructions. The constructs for pET11c-RAD51 and, RPA-eGFP
12 (pMM801) and RPA-mRFP1 (pMM802) were kind gifts from Lumir Krejci (MUNI, Masaryk University,
13 Bruno) and Mauro Modesti (CRCM, Marseille) respectively.

14

15 **Recombinant protein purification**

16 To express proteins in insect cells, bacmid, primary and secondary baculovirus were prepared according
17 to manufacturer's instructions (Bac-to-bac system, Life technologies). To express recombinant MBP-
18 HELQ-FLAG, *Spodoptera frugiperda* (*Sf9*) insect cells were seeded at 500,000/ml and after ~ 24 hrs,
19 cells were infected with MBP-HELQ-FLAG baculovirus. The infected cells were incubated at 27° C for 56
20 hrs with continuous agitation. Cells were harvested by centrifugation at 500 g for 10 min and washed
21 once with 1X PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄). The harvested
22 pellets were snap frozen in liquid nitrogen and stored at -80° C until further use. All subsequent steps
23 were carried out either on ice or at 4° C. The cells pellets were resuspended in 3 volumes of lysis buffer
24 containing 50 mM Tris-HCl pH 7.5, 1 mM ethylenediaminetetraacetic acid (EDTA), protease inhibitor
25 cocktail tablets (Roche), 30 µg/ml leupeptin (Merck), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM
26 dithiothreitol (DTT), 0.1% NP-40 substitute (NP-40) and incubated for 15 min with continuous agitation.
27 Next, 50% glycerol and 5 M NaCl were added sequentially to the final concentrations of 16.7% and 310
28 mM respectively, and suspension was further incubated for 30 min with continuous agitation. The
29 suspension was centrifuged at ~ 48000 g for 30 min to obtain the soluble extract. The amylose resin

30 (NEB) was pre-equilibrated with amylose wash buffer I (50 mM Tris-HCl pH 7.5, 1 mM 2-
31 Mercaptoethanol (β -ME), 1 M NaCl, 1 mM PMSF, 10% glycerol, and 0.1% NP-40) and added to 50 ml
32 tubes containing soluble extract. These tubes were subsequently incubated for 1 h with continuous
33 rotation. Post-incubation, resin was washed batchwise 4x by centrifugation at 2000 g for two min and 2x
34 on column with amylose wash buffer I. Resin was washed two more times on column with amylose wash
35 buffer II (same as wash buffer I but with 0.5 β -ME and 0.8 M NaCl). Protein was eluted from resin with
36 amylose elution buffer (same as amylose wash buffer II supplemented with 10 mM Maltose) and total
37 protein was estimated using Bradford assay. To remove the MBP tag, 1/8 (weight/weight) of PreScission
38 protease (PP) to the total protein added to amylose eluate and incubated for 2 hrs without rotation but
39 gentle agitation at regular intervals. The FLAG resin (anti-FLAG M2 resin, Sigma-Aldrich), pre-
40 equilibrated with FLAG wash buffer (50 mM Tris-HCl pH 7.5, 0.8 M NaCl, 1 mM PMSF, 10% glycerol),
41 added to amylose eluate containing PP and incubated for 2 hrs with continuous rotation. FLAG resin was
42 collected directly on column and washed 6x with FLAG wash buffer. Protein was eluted from FLAG resin
43 with FLAG elution buffer (50 mM Tris-HCl pH 7.5, 0.5 mM β -ME, 150 mM NaCl, 1 mM PMSF, 10%
44 glycerol, 150 ng/ μ l 3XFLAG peptide (Sigma), aliquoted, frozen in liquid nitrogen and stored at -80° C.
45 The same purification procedure was used to purify HELQ K365M.

46

47 Recombinant human RAD51 was purified as described previously with few modifications¹. The pET11c-
48 RAD51 expression vector was transformed in *E. coli* BLR(DE3)pLysS cells and subsequent culture
49 containing ampicillin (100 mg/l) and chloramphenicol (33. mg/l) was grown to ~0.7 O.D at A₆₀₀. RAD51
50 expression was induced with 1 mM Isopropyl β -d-1-thiogalactopyranoside (IPTG) at 37° C for 3-4 hrs. All
51 subsequent steps were carried out either on ice or at 4° C. Cells were harvested by centrifugation at 5000
52 g. Cell pellets were resuspended in cell breakage buffer (CBB) (50 mM Tris-HCl pH 7.5, 10% sucrose,
53 0.5 mM EDTA, 1 M KCl, 1 tablet/50 ml protease inhibitor cocktail tablets (Roche), 1 mM PMSF, 1 mM
54 DTT and 0.01% NP-40), sonicated and centrifuged at 100,000 g for 1 h. To precipitate RAD51, 0.242
55 grams/ml ammonium sulphate was mixed with clarified supernatant and centrifuged for 20 min at 10,000
56 g. The pellet was resuspended with buffer K (20 mM K₂HPO₄ pH 7.5, 10% glycerol, 0.5 mM EDTA, 1 mM
57 DTT, 0.01% NP-40) and loaded on Q Sepharose Fast flow column (Cytiva), pre-equilibrated with K buffer-
58 low (K buffer supplemented with 175 mM KCl). The column was extensively washed with K buffer-low

59 and protein was subsequently eluted with KCl gradient using K buffer-high (K buffer supplemented with
60 0.6 M KCl). The eluted fractions containing RAD51 were pooled and diluted with 6 volumes of dilution
61 buffer (25 mM Tris HCl pH 7.5, 0.5 mM EDTA, 1 mM DTT, 0.01% NP-40). The diluted sample was loaded
62 on HiTrap Heparin HP affinity column (Cytiva), which was pre-equilibrated with buffer H without glycerol
63 (25 mM Tris HCl pH 7.5, 0.5 mM EDTA, 1 mM DTT, 0.01% NP-40, 150 mM KCl) and washed with buffer
64 H containing 10% glycerol. Protein was eluted in buffer H with KCl gradient (0.1 M to 1 M KCl) and
65 fractions containing RAD51 were pooled and dialyzed in buffer H without glycerol. The dialyzed sample
66 was loaded on Mono Q 5/50 GL column (Cytiva), equilibrated with buffer Q (25 mM Tris HCl pH 7.5, 0.5
67 mM EDTA, 1 mM DTT, 0.01% NP-40, 100 mM KCl, 10% glycerol) and column was further washed with
68 buffer Q containing 50 mM KCl but lacking glycerol. RAD51 was eluted from Mono Q column with KCl
69 gradient (0.05 M to 1 M) in buffer Q lacking glycerol. The eluted fractions containing RAD51 were pooled
70 and further concentrated with Vivaspin Centrifugal Concentrator (30 K MWCO). Glycerol was added to
71 concentrated sample to reach final 10% concentration. Finally, samples were aliquoted, frozen in liquid
72 nitrogen and stored at -80°C . The RAD51 C319S mutant was purified using same procedure. RPA-
73 mRFP1 and RPA-eGFP were purified as described previously². Recombinant RecA (M0249) and ET
74 SSB (M2401) were commercially purchased from NEB, England.

75

76 **Preparation of labelled proteins**

77 RAD51 C319S variant was expressed and purified as described earlier for wild type RAD51^{1,3}. After
78 purification, protein was fluorescently labelled with Alexa Fluor 488 C₅ maleimide (Thermo Fisher, cat. n.
79 A10254) according to previously described protocol². Labelled protein was purified away from the free
80 dye using Zeba column gel filtration system (0.5 mL resin, 50.000 MWCO). Protein concentration was
81 estimated by Coomassie staining and dye concentration was measured spectrophotometrically. Presence
82 of minimum free dye concentration was assessed using SDS-PAGE on labelled proteins. Protein to dye
83 concentration ratio was consistently 0.9-1.0. D-loop formation of labelled RAD51 was tested and gave
84 yields comparable to unlabelled wild-type RAD51 protein, consistent with previous reports³. RPA-eGFP
85 and RPA-mRFP1 were expressed and purified as described previously². DNA binding of labelled RPA
86 was tested. All RPA fusion proteins displayed similar ssDNA affinities within nanomolar K_d range.

87

88 **DNA sequences of oligoes used in this study for *in vitro* analysis**

89 The details of DNA substrate preparation and sequence of oligoes used is provided in table 1 and table
90 2 respectively.

91

92 **DNA unwinding assay**

93 The unwinding assays were carried out in 15 μ l helicase buffer containing 25 mM Tris-HCl pH 8.0, 2 mM
94 ATP, 2 mM $MgCl_2$, 1 mM DTT, 50 mM NaCl, 0.1 mg/ml bovine serum albumin (BSA, New England
95 Biolabs), 1 mM PEP (Phosphoenolpyruvate, Sigma-Aldrich), 10 U/ml pyruvate kinase (Sigma-Aldrich)
96 and 5' end FITC (Fluorescein isothiocyanate) labelled 25 nM DNA substrate (in molecules). All steps
97 except assembling reactions, and protein addition were performed in dark. The reactions were assembled
98 on ice and recombinant proteins were added, mixed and incubated at 37° C for 30 mins. The reactions
99 were stopped with 5 μ l of 2% stop solution (0.2% SDS, 30% Glycerol, 150 mM EDTA, bromophenol blue)
100 and 1 μ l Proteinase K (Roche, 18.4 mg/ml) and incubated further for 10 min at 37° C. To prevent
101 reannealing, 2% stop solution was supplemented with 10-fold excess of unlabelled oligo with the same
102 sequence as FITC-labelled one. The products were resolved by 10% native polyacrylamide gel (19:1
103 acrylamide-bisacrylamide, Biorad) using Mini-Protean Tetra Cell electrophoresis system (Biorad) at 100
104 V for 1 h. The gels were directly imaged in ChemiDoc MP imaging system.

105

106 **Quenching-based kinetic assay for DNA unwinding**

107 These assays were carried out in 60 μ l helicase buffer with 20 nM DNA substrate (in molecules). The
108 oligo F (49-mer) in DNA substrate was labelled with 6-flouroscein amidite(6-FAM) at 5' end whereas oligo
109 R (22-mer) was labelled at 3' end with rhodamine (ROX). The reactions were assembled on ice in 96-
110 microwell plate and recombinant proteins were directly added to their respective wells. Microplate was
111 transferred to microplate reader (CLARIOstar, BMG Labtech) at 37° C and 6-FAM intensity was
112 continuously monitored at every 30 seconds for 60 min. The final values were plotted in graph forms
113 using PRISM graphpad.

114

115 **Electrophoretic mobility shift assay**

116 EMSA reactions (15 μ l) were carried out in binding buffer containing 25 mM Tris-HCl pH 8.0, 2 mM ATP,
117 2 mM $MgCl_2$, 1 mM DTT, 50 mM NaCl, 0.1 mg/ml bovine serum albumin (BSA, New England Biolabs)
118 and 5' end FITC (Fluorescein isothiocyanate) labelled 25 nM DNA substrate (in molecules). All steps
119 except assembling reactions, and protein addition were performed in dark. Reactions were assembled
120 on ice and recombinant proteins were added to reactions, mixed and incubated for 10 min at 37° C in
121 dark. Reactions were supplemented with 5 μ l of EMSA loading buffer (50% glycerol, bromophenol blue)
122 and resolved with 6% native TBE polyacrylamide gel (19:1 acrylamide-bisacrylamide, Biorad) using Mini-
123 Protean Tetra Cell electrophoresis system (Biorad) at 80 V for 45 min on ice. Finally, gels were imaged
124 using ChemiDoc MP imaging system.

125

126 **RPA stripping gel-based assay**

127 Stripping assay was performed as described for EMSA except products were resolved at room
128 temperature and longer 6% TBE native gel was used.

129

130 **DNA annealing assay**

131 DNA annealing assays were carried out in 15 μ l annealing buffer containing 25 mM Tris-HCl pH 8.0, 2
132 mM ATP, 2 mM $MgCl_2$, 1 mM DTT, 50 mM NaCl and 0.1 mg/ml bovine serum albumin (BSA, New England
133 Biolabs). All steps except assembling reactions, and protein addition were performed in dark. For DNA
134 substrate, 10 nM (in molecules) complementary oligos (5' FITC-Oligo 1 and oligo 2) were separately
135 incubated in 7.5 μ l annealing buffer and as indicated, with or without RPA on ice for 2 min. Recombinant
136 proteins were added to FITC-oligo 1 reactions (7.5 μ l) on ice, immediately followed by the addition of
137 oligo 2 reactions (7.5 μ l). Reactions were incubated for 10 min at 37° C. The final concentration of both
138 individual oligo and annealed dsDNA product was 5 nM. The reactions were stopped with 5 μ l of 2% stop
139 solution (0.2% SDS, 30% Glycerol, 150 mM EDTA, bromophenol blue) and 1 μ l Proteinase K (Roche,
140 18.4 mg/ml) and incubated further for 10 min at 37° C. To prevent the detection of spontaneous annealing
141 during deproteination, 25-fold excess of unlabelled oligo 1 to FITC-oligo 1 was included in 2% stop
142 solution. The products were resolved and imaged identically as described for unwinding assays.

143

144 **Interaction assay**

145 To study the interaction in between HELQ and RAD51, MBP-HELQ-FLAG baculovirus was expressed in
146 300 ml insect cells and soluble extract from collected pellet was prepared as described for protein
147 purification procedure. Reagent volumes for soluble extract preparation were scaled down accordingly.
148 Soluble extract was divided equally into two parts and incubated with amylose (E8021, NEB), and anti-
149 FLAG M2 resin (A2220, Sigma-Aldrich) for 1 h at 4 C. Next, amylose resin and anti-FLAG M2 resin were
150 washed with wash buffer I (50 mM Tris-HCl pH 8.0, 1 mM DTT, 310 mM NaCl, 10% glycerol, 1 mM
151 PMSF). Both resins were divided into 50 μ l volumes in separates microtubes. 4 μ g recombinant RAD51
152 was added to all except one tube for each resin and incubated for 1 h at 4° C. Resins were washed with
153 wash buffer II (same as wash buffer I but containing 100 mM NaCl). Proteins were eluted from resin in
154 1X SDS buffer by boiling at 95°C for 4 min. The eluate was separated by 4-12% native SDS-PAGE gel
155 (NuPAGE Bis-Tris, Invitrogen) and stained with instant blue Coomassie protein stain (Abcam).

156

157 **DNA capture assay**

158 The capture assays were carried out in 20 μ l DNA annealing buffer supplemented with 0.05% Tween-20.
159 Reactions were assembled on ice and where indicated, 82 nM RPA, 10 nM biotinylated dT43 (bio-dT43)
160 and 10 nM 3'Cy3-dT79 were added to reactions. Next, HELQ was added to reactions as indicated.
161 Reactions were mixed and incubated at 37° C for 8 mins in dark. To pull down bio-dT43, magnetic
162 streptavidin beads were washed 2X with PBS-0.1% Tween 20 (Dynabeads M-280, ThermoFisher) and 5
163 μ l bread were added to each reaction. Reactions were further incubated for 4 min in dark at room
164 temperature and then washed 2X with 80 μ l washing buffer (25 mM Tris-HCl pH 8.0, 2 mM ATP, 2 mM
165 $MgCl_2$, 1 mM DTT, 100 mM NaCl, 0.5 mg/ml bovine serum albumin, NP-40) on magnetic rack. Finally,
166 beads were resuspended in 30 μ l loading buffer (7.5 μ l 2% STOP solution and 22.5 μ l washing buffer)
167 and boiled at 95° C for 4 min. Sample were centrifuged at high speed for a min and 25 μ l volume sample
168 was loaded immediately on 10% native polyacrylamide gel and ran as described for unwinding assay.
169 The gels were directly imaged in ChemiDoc MP imaging system (Biorad).

170

171 **Substrate and flow cell preparation for single-molecule imaging**

172 Experiments were performed using commercially available C-trap (LUMICKS) setup. Protein channels of
173 the microfluidics chip were first passivated with BSA (0.1% w/v in PBS) and Pluronics F128 (0.5% w/v in

174 PBS), minimum 500 μ l of both flowed through prior to use. Biotinylated ssDNA precursor was prepared
175 as described previously⁴. To generate gapped λ DNA, a protocol described previously was employed⁵.
176 Briefly, biotinylated hairpin oligonucleotides were annealed to ds- λ DNA ends and ligated⁶. *S. p.* Cas9
177 D10A nickase (IDT) bound to previously described⁷ guide RNAs were subsequently used to generate
178 targeted DNA nicks. The reaction was then stored at 4 °C and directly diluted in PBS on the day of the
179 experiment. DNA was captured between 4.5- μ m SPHERO Streptavidin Coated polystyrene beads at
180 0.005% w/v using the laminar flow cell, stretched and held at forces of 100 pN (for ssDNA) or 65 pN (λ
181 gDNA 4/5) until the strands were fully melted. The presence of ssDNA and/or ssDNA gap was verified by
182 comparison to built-in freely joined chain model. For confocal imaging, three excitation wavelengths were
183 used, 488 nm for eGFP and Alexa Fluor 488, 532 nm for Cy3 and 638 nm for Cy5, with emission detected
184 in three channels with blue filter 512/25 nm, green filter 585/75 nm and red filter 640 LP.

185

186 **Single-molecule DNA unwinding assay**

187 For all the unwinding assays λ gDNA 4/5 construct was held at constant force of 50 pN. Beads and DNA
188 were kept in PBS during the experiment, while DNA was melted in 0.5xNTM buffer (25 mM Tris-HCl pH
189 7.5, 50 mM NaCl, 0.5 mM MgCl₂) supplemented with 0.2 mg/ml BSA and 1 mM DTT. 50 nM HELQ and/or
190 25 nM RAD51(A488) were flowed into the system in 1xHELQ buffer (25 mM Tris-HCl pH 8.0, 2 mM MgCl₂,
191 50 mM NaCl) supplemented with 2 mM ATP, 0.2 mg/ml BSA and 1 mM DTT. Unwinding was monitored
192 by change in distance between the beads over time. To directly image fluorescent RAD51, following
193 image acquisition setup was employed: 5% blue laser power, 0.1 ms/pixel dwell-time, 100 nm pixel size,
194 1 s inter-frame wait time.

195

196 **Single-molecule DNA oligonucleotide capture assay**

197 For all the unwinding assays λ ssDNA was held at constant force of 10 pN. Beads and DNA were kept in
198 PBS during the experiment, while DNA was melted in 0.5xNTM buffer (25 mM Tris-HCl pH 7.5, 50 mM
199 NaCl, 0.5 mM MgCl₂) supplemented with 0.2 mg/ml BSA and 1 mM DTT in the presence of 5 nM RPA-
200 eGFP. 5 nM HELQ, 5 nM RPA-eGFP and 2 nM 5'Cy3-(λ 4)80 oligonucleotide (5'-Cy3-
201 CCTGAACGACCAGGCGTCTTCGTTTCATCTATCGGATCGCCACACTCACAACAATGAGTGGCAGAT
202 ATAGCCTGGTGGTTC-3') or 2 nM 5'Cy3-(dT)79 oligonucleotide (5'-Cy3-

229 The resulting function $MSD(interval\ time)$ generated a plot which can be linear in the case of
230 unconstrained 1D diffusion, partially linear (at short interval times) in the case of constrained diffusion,
231 quadratic for unidirectional movement, and flat in the case of a stationary molecule.

232
233 To estimate the average velocity of the translocating molecule, the total route of the molecule (a sum of
234 frame-to-frame displacements) was divided by the total trajectory time. Here, every trajectory was
235 smoothed using Savitzky-Golay filter (smoothing factor = 51) to eliminate tracking inaccuracies and to
236 minimize the effect of thermal fluctuations of the DNA tether on the frame-to-frame displacements.

237
238 To estimate the loop size formed by the HELQ-RPA-DNA complex, the contour length after each
239 unfolding event in the force-distance curve was fitted by the Worm-Like-Chain model. The difference
240 between contour lengths of the neighbouring events corresponds with the loop size.

241 242 **RPA stripping via single Molecule FRET**

243 Flow chambers were prepared as described previously^{1,2}. Quartz slides and coverslips were passivated with
244 polyethylene glycol (5% biotinylated) and flow chambers constructed using double-sided sticky tape and sealed
245 with epoxy. 5'-biotin and internal amino linker modified DNA oligonucleotides were labelled with Cy3-NHS ester
246 and HPLC purified as previously described³. DNA (6 pM) was immobilised via biotin-streptavidin interactions.
247 All experiments we performed in the standard HELQ buffer with addition of the PCA/PCD oxygen scavenger
248 system with 5 mM PCA, 100 nM PCD and saturating Trolox. The flow chambers were imaged on a home-built,
249 prism-based total internal reflection microscope with a 532nm excitation laser (~3.8 mW), and images acquired
250 on an EM-CCD camera (Andor) with a 30 ms exposure time. FRET efficiencies were calculated from integrated
251 donor (I_D) and acceptor (I_A) intensities as $FRET = I_A / (I_D + I_A)$ ^{1,3}. Images and data were analysed by custom IDL,
252 MATLAB and R scripts, available upon request. FRET efficiency histograms were constructed by averaging the
253 first 10 frames of each trajectory, with bins of 0.1. The dwell times of the free (high FRET) and bound (low FRET)
254 states were measured, and dwell-time histograms plotted. These were fit with single exponential fits to obtain
255 average dwell times.

256 257 **Cell culture**

258 U2OS, human osteosarcoma cell line, was grown in DMEM supplemented with 10% bovine growth serum
259 (BGS), 2 mM L-glutamine, 100 µg/mL streptomycin, and 100 units/mL penicillin. U2OS-EJDR cells were
260 cultured in DMEM supplemented with 10% tetracycline-free fetal bovine serum (FBS), 2 mM L-glutamine,
261 100 µg/mL streptomycin, and 100 units/mL penicillin. U2OS-DR cells contain a stably integrated DR-GFP
262 reporter to measure DSB repair by HR as previously described⁸. U2OS-SA cells contain a stably
263 integrated SA-GFP reporter to measure DSB repair by SSA as previously described⁹. U2OS-DR cells
264 containing a stably integrated EJ-RFP reporter to measure DSB repair by mutagenic end-joining,
265 constitute the U2OS-EJDR cell line as previously described¹⁰. U2OS-RFP-SCR cells contain a stably
266 integrated RFP-SCR reporter for quantifying short and long tract gene conversion in HR as previously
267 described¹¹.

268

269 U2OS-DR HELQ^{-/-} and U2OS-SA HELQ^{-/-} cells were generated using the CRISPR-Cas9 system.
270 Knockouts verified by Sanger sequencing and immunoprecipitation/western blot.

271

272 *siRNA*

273 siRNA oligonucleotides used to transiently deplete HELQ: HelQsp (Horizon siGENOME SMARTpool, M-
274 015379-01-0005), HelQ_M⁴ (CAAAGGAAGATTTCTCCAATAAA), HelQ_4 (Qiagen FlexiTube siRNA,
275 TTGGGTGATCATTCTATGAAA). RAD52 was depleted with On-Target plus SMART pool siRNA L-
276 011760-00-0005 (Horizon). BRCA2 was depleted with On-Target plus SMART pool siRNA L-003462-00-
277 0005 (Horizon). On-Target plus Non-targeting siRNA pool used for NT controls (D-001810-10-05,
278 Horizon).

279

280 **DSB repair assays**

281 0.25×10^6 cells were reverse transfected with 30 pmol siRNA using Lipofectamine RNAiMAX Reagent
282 (Invitrogen) according to manufacturer instructions. After 48 hours, cells were transfected with 2 µg of
283 pCMV-*I*SceI-3xNLS or pCMV 3xNLS empty vector and 30 pmol siRNA using Lipofectamine 2000
284 (Invitrogen). Cells were harvested for analysis by flow cytometry at 72 hours using the LSR Fortessa
285 instrument (BD Biosciences). For each experiment, % GFP or RFP positive cells in the empty vector
286 control was subtracted from the *I*-SceI transfected cells. Data from each reporter assay represents the

287 mean and standard error of at least 3 independent experiments, and statistical analysis was performed
288 using a two-tailed paired t-test.

289

290 **Immunoprecipitation/Western blot**

291 Cells were lysed in RIPA buffer (Teknova, cat#R3792) with HALT protease inhibitor cocktail (Thermo
292 Scientific). As HELQ is expressed at low levels in human cell lines and commercially available antibodies
293 tested did not dependably detect endogenous HELQ by western blot, we validated siRNA mediated
294 HELQ knockdown by HELQ immunoprecipitation. 10^6 cells were transfected with 2 μ g siRNA by
295 electroporation using the Amaxa nucleofector system, and plated into 150mm dishes. After 72 hours,
296 cells were harvested and whole cell extracts were used for immunoprecipitation. 2mg protein was
297 incubated with 1 μ g HEL308 antibody (Novus Biologicals NBP1-91842) at 4°C overnight with rotation.
298 After washing 0.25mg Pierce Protein A/G Magnetic Beads (Thermo Scientific cat #88802), the antigen
299 sample/antibody mix was added to the beads and incubated for 1 hour at room temperature with rotation.
300 The beads were washed four times and eluted in SDS-PAGE reducing sample buffer (Invitrogen) for ten
301 minutes at 96°C. Samples were loaded onto 4-12% Bis-Tris precast gels (Invitrogen) for SDS-gel
302 electrophoresis and transferred onto Immobilon-P PVDF membrane (Millipore). Membranes were
303 blocked for one hour at room temperature with Pierce clear milk blocking buffer. For Western blot analysis
304 of RAD52 and BRCA2, 50 μ g of protein was loaded onto 10% Bis-Tris or 3-8% Tris-Acetate precast gels
305 (Invitrogen) for SDS-gel electrophoresis. Proteins were transferred onto a PVDF (polyvinylidene
306 difluoride) membrane (BioRad) for BRCA2 detection. The iBlot Gel Transfer System (Invitrogen) was used
307 to perform dry blotting of proteins onto nitrocellulose membranes for RAD52 detection. Membranes were
308 blocked for one hour at room temperature with Pierce clear milk blocking buffer. Antibodies for Western
309 blot: anti-HEL308 (Santa Cruz Biotechnology, sc-81095), anti-RAD52 (Santa Cruz Biotechnology, sc-
310 365341), anti-Actin (Millipore Sigma, MAD1501), anti-BRCA2 Ab-1 (Millipore Sigma, OP95), anti-SMC1
311 (Bethyl laboratories, A300-055A).

312

313 **Software**

314 Statistical analysis was carried out using Graphpad Prism (version 8.4).

315 Flow cytometry data was analyzed using BD FlowJo (version 10.6).

316 Schematics for reporter assays designed using Biorender.com.

317

318 **Table. 1 Detail of preparation of *in vitro* substrates**

DNA substrates	Annealed oligos
ssDNA	Oligo 1
3' overhang	Oligo 1 + Oligo 4
5' overhang	Oligo 1 + Oligo 5
dsDNA	Oligo 1 + Oligo 2
Y structure	Oligo 1 + Oligo 6
Lagging-strand fork	Oligo 1 + Oligo 4 + Oligo 6
D-loop	Oligo 23 + Oligo 22 + Oligo 21 + Oligo 20
3' overhang (used for Quenching kinetic assay)	Oligo F + Oligo R

319

320 **Table. 2 DNA sequence of oligos used in *in vitro* analysis**

Oligos	DNA sequence (5' to 3')
Oligo 1	5' FITC -AGCTACCATGCCTGCACGAATTAAGCAATTCGTAATCATGGTCATAGCT (49-mer)
Oligo 2	5'AGCTATGACCATGATTACGAATTGCTTAATTCGTGCAGGCATGGTAGCT 3' (49-mer)
Oligo 4	5' AATTCGTGCAGGCATGGTAGCT 3' (22-mer)
Oligo 5	5' AGCTATGACCATGATTACGAATTGCTT 3' (27-mer)
Oligo 6	5' AGCTATGACCATGATTACGAATTGCTTGGAATCCTGACGAACTGTAG 3' (47-mer)
Oligo 23	5' FITC -GACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCACCTGCAG GTTCACCC 3' (61-mer)
Oligo 22	5' GGGTGAACCTGCAGGTGGGCGGCTGCTCATCGTAGGTTAGTTGGTAGAATTCG GCAGCGTC 3' (61-mer)
Oligo 21	5' TAAGAGCAAGATGTTCTATAAAAGATGTCCTAGCAAGGCAC 3' (41-mer)
Oligo 20	5' TATAGAACATCTTGCTCTTA 3' (20-mer)
Oligo F	5' 6-FAM -AGCTACCATGCCTGCACGAATTAAGCAATTCGTAATCATGGTCATAGCT (49-mer)
Oligo R	5' AATTCGTGCAGGCATGGTAGCT 3' ROX (22-mer)

- 342 8 Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed
343 repair of DNA damage in mammalian cells. *Genes Dev* **13**, 2633-2638,
344 doi:10.1101/gad.13.20.2633 (1999).
- 345 9 Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps of mammalian
346 homologous repair with distinct mutagenic consequences. *Mol Cell Biol* **24**, 9305-9316,
347 doi:10.1128/MCB.24.21.9305-9316.2004 (2004).
- 348 10 Bindra, R. S., Goglia, A. G., Jasin, M. & Powell, S. N. Development of an assay to measure
349 mutagenic non-homologous end-joining repair activity in mammalian cells. *Nucleic Acids Res*
350 **41**, e115, doi:10.1093/nar/gkt255 (2013).
- 351 11 Chandramouly, G. *et al.* BRCA1 and CtIP suppress long-tract gene conversion between sister
352 chromatids. *Nature Communications* **4**, 2404, doi:10.1038/ncomms3404 (2013).

353

354 **Acknowledgments**

355 We thank Lumir Krejci (MUNI, Masaryk University, Bruno) and Mauro Modesti (CRCM, Marseille) for
356 kindly providing the expression constructs for RAD51 and RPA.

357 **Author contributions**

358 R.A, E.B, S.P and S.B conceived, planned and performed majority of experiments and wrote the paper.
359 O.B and M.N performed and analysed SMI and FRET-based experiments. A.K analysed part of SMI-
360 based DNA capture experiments with D.R. All authors contributed to assemble and finalize the
361 manuscript.

362 **Conflict of interest**

363 S.J.B. is also cofounder and VP Science Strategy at Artios Pharma.